MOTS-c remains an investigational research compound. This article is for research purposes only and does not provide human dosing, treatment, or administration instructions.

For UK and European researchers, the most important development in MOTS-c research this year is not a published result. It is the registration of an ongoing Phase 2a clinical trial: NCT07505745, also known as MOTS-MET.

The study is evaluating MOTS-c in adults with prediabetes and overweight or obesity. However, the registry currently shows no posted efficacy or safety results. Trial registration is evidence that a study has been planned and entered into a public registry. It is not evidence that the intervention works.

The correct approach is to read the protocol, recruitment status, endpoints, and limitations separately.

What NCT07505745 is designed to investigate

According to the ClinicalTrials.gov record for NCT07505745, MOTS-MET is a randomised, placebo-controlled, parallel-group Phase 2 study sponsored by Hudson Biotech.

The registry describes:

• An estimated enrolment of 120 adults.
• Adults aged 18 to 65.
• Prediabetes, defined using HbA1c, fasting plasma glucose, or a 75 g oral glucose tolerance test.
• BMI between 27.0 and 40.0 kg/m².
• A 12-week treatment period.
• A four-week post-treatment safety follow-up.
• Random allocation to MOTS-c or matching placebo.
• Standardised lifestyle counselling in both groups.
• A recruiting site at Peking University Shenzhen Hospital in Shenzhen, China.

The study record was last posted as updated on 1 April 2026, with the status listed as Recruiting. Its estimated primary completion date is February 2027, and estimated full study completion is May 2028.

These dates are estimates, not guarantees. Recruitment, follow-up, analysis, and results reporting can all take longer than expected.

How to interpret “Recruiting”

“Recruiting” has a narrow meaning. It indicates that the study is currently seeking or enrolling eligible participants according to the registry record.

It does not tell you:

• How many participants have been enrolled.
• Whether recruitment is on schedule.
• Whether the intervention is tolerated.
• Whether the primary endpoint has been achieved.
• Whether the study will produce a positive result.
• Whether the compound is suitable for clinical use.

ClinicalTrials.gov explains that the sponsor or investigator submits the study information and remains responsible for the accuracy of the record. The National Library of Medicine performs a limited quality-control review, but that review does not verify the scientific validity of the study or confirm that the intervention is effective.

For that reason, researchers should treat registration as a source of prospective protocol information, not as a conclusion.

What the trial is measuring

The primary efficacy endpoint is the change from baseline in OGTT-derived insulin sensitivity after 12 weeks. The registry identifies the Matsuda Index as the measure calculated from a 75 g oral glucose tolerance test.

This is important because the trial is not simply asking whether a participant’s weight changes. It is designed around a specific metabolic endpoint derived from glucose and insulin measurements during an OGTT.

The primary safety endpoint is the incidence of treatment-emergent adverse events across the 16-week observation period.

Secondary measures include:

• HbA1c.
• Fasting glucose.
• Two-hour glucose during the OGTT.
• Immunogenicity, including anti-drug antibodies where applicable.

A well-designed endpoint helps reduce ambiguity. It also creates limits. A change in the Matsuda Index would not automatically establish a long-term clinical benefit. Likewise, an absence of reported adverse events in a small, short study would not establish long-term safety.

Researchers should wait for the full results before drawing conclusions. That means reviewing the participant flow, baseline balance between groups, missing data, analysis population, confidence intervals, adverse-event tables, and any protocol deviations.

Why the biological rationale is not the same as clinical evidence

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by the mitochondrial genome. Earlier work has examined its possible involvement in metabolic signalling, including AMPK-related pathways and insulin action.

The foundational preclinical paper by Lee and colleagues reported metabolic effects in mouse models, including aged and diet-induced obese animals.[1] Subsequent work has examined plasma MOTS-c associations with metabolic markers in human observational studies.

For example, Du and colleagues reported lower circulating MOTS-c levels in obese male children and adolescents, with associations involving insulin resistance markers.[2] Cataldo and colleagues reported an association between plasma MOTS-c and insulin sensitivity in lean, but not obese, individuals.[3]

These findings are relevant to hypothesis formation. They do not demonstrate that administering MOTS-c improves insulin sensitivity in humans.

That distinction is precisely why NCT07505745 matters. It is designed to test an intervention against placebo in a defined human population. Until the trial reports results, the efficacy question remains open.

What UK researchers should check in a research supplier

The UK research environment is placing greater emphasis on transparency, traceability, and the boundary between research-use-only materials and medicines.

A research-use-only, or RUO, compound is not an approved medicine. It must not be presented for human consumption, clinical treatment, or self-administration. If a product is intended for administration in a human clinical trial, it falls within a different regulatory framework. UK clinical trial reforms that came into force on 28 April 2026 reinforce expectations around authorisation, transparency, and the responsible handling of investigational medicinal products.[4][5]

For laboratory research, sourcing documentation should be assessed with the same discipline as the experimental protocol. At a minimum, please look for:

1. A batch-specific certificate of analysis

The lot or batch number on the certificate should match the vial and packaging you receive. A generic certificate covering several batches does not provide the same level of verification.

The certificate should show the test date, issuing laboratory, analytical methods, results, and acceptance criteria where available.

2. Identity and purity testing

Identity testing helps establish that the material corresponds to the stated compound. Techniques such as mass spectrometry can be used to compare observed and theoretical molecular mass.

Purity testing, commonly reported by HPLC, should show an actual result for the relevant batch. A headline purity figure without a lot number, method, or named laboratory provides limited assurance.

Researchers sourcing AXIOM MOTS-c for laboratory research should review the available product and quality documentation before placing an order. AXIOM’s stated quality framework includes identity verification, purity validation, molecular-weight confirmation, and stability assessment.

3. Endotoxin and heavy-metal screening where relevant

The appropriate test panel depends on the research model. Endotoxin data can be important for work involving biological systems where contamination could affect results. Heavy-metal screening may also be relevant depending on the material, synthesis route, application, and institutional requirements.

RUO status does not automatically mean sterile, endotoxin-free, or suitable for every model. Ask what has been tested for the specific batch. Where necessary, use an institutional analytical core or qualified laboratory for additional confirmation.

4. Documented chain of custody

Traceability should not end when the parcel is dispatched. Record:

• Supplier and purchase reference.
• Product name and batch number.
• Certificate of analysis version.
• Dispatch and receipt dates.
• Packaging condition on arrival.
• Storage location and temperature records where relevant.
• Any transfer between laboratories or researchers.

This creates an auditable link between the material described in the protocol and the material used in the experiment.

Where NAD+ fits into the research context

NAD+ is a coenzyme involved in cellular redox reactions and energy metabolism. It is not the same compound as MOTS-c, and it should not be treated as a substitute or comparator unless the research protocol specifically defines that role.

Researchers investigating related cellular pathways can review the AXIOM NAD+ research compound separately. The important principle is to define the research question first, then select materials based on identity, formulation, documentation, and model-specific requirements.

A catalogue relationship between two compounds does not establish a mechanistic or clinical relationship between them.

What to look for when results become available

When NCT07505745 reports results, read the full dataset rather than relying on a headline. Focus on:

1. The analysed population: Was the analysis intention-to-treat, per-protocol, or both?
2. The primary endpoint: What was the between-group difference in the Matsuda Index?
3. Uncertainty: Were confidence intervals reported, and how wide were they?
4. Missing data: How many participants withdrew or failed to complete follow-up?
5. Safety: What adverse events occurred, and were there group imbalances?
6. Generalisability: Can findings from one site in Shenzhen be applied to UK or European research populations?
7. Duration: Does a 12-week outcome answer the longer-term question being asked?
8. Replication: Are the findings consistent with later trials and independent analyses?

Until then, the scientifically accurate position is simple: MOTS-c has a plausible research history and an ongoing human trial, but its clinical efficacy and safety remain undetermined.

Source MOTS-c research material with documentation

If you are planning in-vitro or analytical peptide research, begin with the protocol and define the documentation your model requires. Review AXIOM’s quality and testing framework, confirm the batch-specific paperwork, and retain the full traceability record for your study files.

You can also use the AXIOM Research Compendium for structured background on peptide signalling, mitochondrial biology, experimental models, and evidence limits.

For research sourcing, review the AXIOM MOTS-c listing and contact our team before ordering to confirm current batch documentation and suitability for your intended laboratory application.

References

1. Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009
2. Du C, Zhang C, Wu W, et al. “Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance.” Pediatric Diabetes. 2018;19(6):1058–1064. doi:10.1111/pedi.12685
3. Cataldo LR, Fernández-Verdejo R, Santos JL, et al. “Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.” Journal of Investigative Medicine. 2018;66(6):1019–1022. doi:10.1136/jim-2017-000681
4. Medicines and Healthcare products Regulatory Agency. Clinical trials for medicines: apply for authorisation in the UK.
5. Health Research Authority. Clinical trials regulations reform.
6. ClinicalTrials.gov. NCT07505745: MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity.

Research-use-only notice: AXIOM compounds are supplied for laboratory research and analytical investigation only. They are not medicines, dietary supplements, or products for human or veterinary use. No human dosing or treatment instructions are provided.